Clinical trial · Observational
Patient Characteristics, Treatment Patterns, and Healthcare Resource Utilization of Metastatic Melanoma Patients
Non-interventional Register-based Study to Analyze Patient Characteristics, Treatment Patterns and Healthcare Resource Utilization in Adult Patients With Metastatic Melanoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This was a retrospective, non-interventional, registry study based on secondary electronic medical record (EMR) data collected in Helsinki and Uusimaa hospital district (HUS data lake), hospital district of Southwest Finland (VSSHP data lake) and Pirkanmaa hospital district (PSHP data lake) as a part of their routine clinical practice. Social Insurance Institution of Finland (SII; reimbursed drug purchases) was utilized in this study to complement the medication data. The metastatic melanoma patients were stratified by first-line treatment and by hospital district.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Melanoma | Melanoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Distant Metastasis Cohort
- description
- Adult patients diagnosed with stage 4 (distant) metastatic melanoma between 2014 and 2021.
- label
- Regional Metastasis Cohort
- description
- Adult patients diagnosed with stage 3 (regional) metastatic melanoma between 2014 and 2021.
Primary outcomes (15)
- measure
- Mean Age-standardized Annual Incidence of Metastatic Melanoma in 2014-2021
- timeFrame
- Up to approximately 7 years
- measure
- Point Prevalence per 100,000 Population
- timeFrame
- Up to approximately 7 years
- description
- Point prevalence was defined as the number of metastatic melanoma patients alive at the end of 2021 divided by the total of hospital districts of Helsinki and Uusimaa hospital district (HUS), Pirkanmaa hospital district (PSHP), and Hospital district of Southwest Finland (VSSHP).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria * Patients diagnosed with metastatic melanoma (C43) during 01 January 2014 and 31 December 2021. * Adult (18 years or older) at the time of diagnosis of metastatic melanoma. * Resident in the corresponding hospital district(s) at the time of diagnosis of metastatic melanoma. Exclusion criteria * Metastasis recorded prior to 01 January 2014 (i.e. prevalent case). * Record of any other cancer (The International Classification of Diseases, 10th Revision \[ICD-10\] diagnosis code starting with C, excluding C43, C77, C78, and C79) as last cancer diagnosis before metastasis. * Participated in COBRA (vemurafenib, temozolomide, lomustine, vincristine) trial.
References
Publications (0)
Data not yet available